Enter your search terms:
Top

Uncategorized

Patent Infringement Suit Against BDSI

COMPLAINT ALLEGES INFRINGEMENT ON MULTIPLE CLAIMS IN MONOSOL RX’S U.S. PATENT NO. 8,765,167 BY BDSI’S BELBUCA™ WARREN, N.J., January 13, 2017 – MonoSol Rx, a specialty pharmaceutical company utilizing its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today filed a...

MonoSol Rx Receives FDA Acceptance of Investigational New Drug Application for Riluzole Oral Soluble Film to Treat Amyotrophic Lateral Sclerosis

WARREN, N.J., January 4, 2017 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application...

U.S. Patent and Trademark Office Upholds the Validity of MonoSol Rx’s US Patent No. 8,765,167 in the Face of Multiple Inter Partes Review Challenges Brought by BioDelivery Sciences International, Inc. (BDSI)

WARREN, N.J., April 7, 2016 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Patent and Trademark Office (USPTO) has upheld the validity of all challenged claims...